Treatment of chronic plaque psoriasis: An overview on current update

Introduction

Chronic plaque psoriasis is an inflammatory skin disorder that affects 2–3% of the population. The severity of the disease is influenced by the number and location of skin lesions, concomitant conditions such psoriatic arthritis, and the impact on daily life. Several comorbidities, such as depression, cardiometabolic disorders, and psoriatic arthritis, are linked to plaque psoriasis. Hence, aim of current review is to highlight the comprehensive information on the pathophysiology, mechanism of action of recent approved drugs and future prospective. Further, clinical research and lengthy prospective cohort studies have been discussed.

Materials and methods

The data were collected from the various reported literatures PubChem, scopus and other search engines which are suggesting for the management of plaque psoriasis. These literature review were selected based on the current updated treatment of chronic plaque psoriasis.

Result

Various biologics have been promoted by the National Psoriasis Foundation guidelines as a first-line treatment option for moderate to severe plaque psoriasis due to their effectiveness in treating the condition and their acceptable safety profiles. The aryl hydrocarbon receptor (AhR) modulator tapinarof, the phosphodiesterase-4 (PDE4) inhibitor roflumilast and the tyrosine kinase 2 (TYK2) inhibitor deucravacitinib are the new drugs approved by US Food and Drug Administration (FDA) for promising treatment mild-severe plaque psoriasis.

Discussions

The conventional systemic therapy for treatment of plaque psoriasis was found to be unsatisfactory due to several significant adverse effects and contraindications. It is vital to continue developing efficacious, safe, and tolerant systemic medication approach capable of being employed as first-line systemic treatments for those with moderate-to-severe psoriasis. The recent approved drugs by USFDA for the management of psoriasis offer the potential for enhanced efficacy and better disease control.